U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06953765) titled 'A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer' on April 23.
Brief Summary: In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) against non-small cell lung cancer (NSCLC). However, there are significant individual differences in patient response to treatment. Studies have shown that sleep disorders may affect the function of the immune system, thereby affecting tumor progression and treatment response. Therefore, the aim of this study was to evaluate the impact of sleep ...